Status:
COMPLETED
Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
Lead Sponsor:
Catalysis SL
Conditions:
Depression
Post-COVID-19 Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clinical depression is a mood disorder that affects people of all ages with symptoms such as sadness, anger or frustration, appetite changes, difficulty concentrating and suicidal thoughts. Psychologi...
Detailed Description
Clinical depression is a mood disorder where feelings of sadness, anger or frustration interfere with daily life for a prolonged period of time. It can affect people of all ages, presenting symptoms s...
Eligibility Criteria
Inclusion
- Patients with clinical depression diagnosed primary or secondary to concomitant illness or post COVID-19.
Exclusion
- Patients with psychological disorders in addition to depression, such as anxiety, attention deficit, hyperactivity disorder, post-traumatic stress disorder other than that caused by COVID-19, bipolar disorder or other mental disorders secondary to depression.
- Patients with severe depression requiring antidepressant medication.
- Patients who ingest psychoactive substances.
Key Trial Info
Start Date :
November 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06496087
Start Date
November 1 2022
End Date
April 15 2024
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundación CR INVESTIGATION INSTITUTE
Bogotá, Bogotá DC, Colombia, 110131